CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors
September 15 2021 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, today announced the
appointment of Joanne Yun, Ph.D. as an independent director on the
company’s Board, effective September 14, 2021. Dr. Yun brings
extensive research and development, commercial, and governance
experience from the pharmaceutical industry.
"We are very pleased to add Dr. Yun as an
independent director and look forward to her strategic input as we
continue to develop our diverse pipeline of novel mitochondria
based therapeutics," said David Greenwood, Chairman of CohBar.
"Joanne has a wealth of industry experience with a large,
impressive network. Her deep understanding of the biotechnology and
pharmaceutical industries will provide significant
contributions."
“I am quite excited to join CohBar’s Board and
believe the company is well positioned to address a number of
important medical conditions in need of new therapies,” stated Dr.
Yun. “CohBar’s unique approach to developing novel peptide
therapeutics provides multiple independent opportunities for
success, with the potential to make a real difference in the lives
of patients. I look forward to working closely with the management
team and the rest of the Board to advance the company’s pipeline
and build on the recent success of the positive topline data from
the CB4211 clinical trial.”
Dr. Yun is a partner at Egon Zehnder, one of the
world’s preeminent leadership advisory firms and is currently a
member of the firm’s Health Practice. In addition to her board and
executive leadership work for global pharmaceutical and
biotechnology companies, Dr. Yun leads the Research &
Development segment of Egon Zehnder’s Health Practice.
Prior to joining Egon Zehnder, Dr. Yun was a
Director in the Global Oncology Business Unit for Bayer HealthCare
Pharmaceuticals with responsibility for oncology program management
and new product planning. She has advised on all aspects of
research, development, and commercial strategies, including
portfolio prioritization, business development, alliance
governance, and merger integration. Dr. Yun started her career with
Bayer AG as a Bench Chemist and Laboratory Head in the Organic
Synthesis Department of Bayer’s Central Research Division in
Leverkusen, Germany. She later transitioned into the Corporate
Research & Development Planning Department for the Bayer AG
Board of Management and then joined the Strategic Planning
Department for the Pharmaceuticals Division, where she focused on
global merger & acquisition strategies and transactions. Dr.
Yun subsequently transferred to Bayer’s North America Business
Development & Licensing group.
Dr. Yun earned a bachelor’s degree in chemistry
and French from Amherst College and a Ph.D. in chemistry from the
Massachusetts Institute of Technology. She was a National
Institutes of Health (NIH) Postdoctoral Fellow at The Scripps
Research Institute and is a member of the American Society of
Clinical Oncology, the American Society of Hematology, and the
American Chemical Society.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage
biotechnology company focused on the research and development of
mitochondria based therapeutics, an emerging class of drugs for the
treatment of chronic and age-related diseases. Mitochondria based
therapeutics originate from the discovery by CohBar’s founders of a
novel group of naturally occurring peptide sequences within the
mitochondrial genome, some of which have been shown to have the
potential to regulate key processes in multiple systems and organs
in the body. To date, the company has discovered more than 100
mitochondrial derived peptides and generated over 1,000 analogs.
CohBar’s efforts focus on the development of these peptides into
therapeutics that offer the potential to address a broad range of
diseases associated with the underlying impact of mitochondrial
dysfunction. The company’s lead compound, CB4211, which is under
development for the treatment of NASH and obesity, recently
completed a successful Phase 1a/1b clinical trial. In addition,
CohBar has four preclinical programs, the most advanced of which is
CB5138-3, a peptide with broad anti-fibrotic and anti-inflammatory
properties. This program is currently in IND-enabling studies with
the goal of filing an IND and initiating a First-in-Human study in
2022 with an initial indication of idiopathic pulmonary fibrosis.
The company also has a program in ARDS, including COVID-19
associated ARDS, as well as two peptide families with potential
utility in treating various forms of cancer.
For additional company information, please visit
www.cohbar.com.
Forward-Looking Statements
This news release contains forward-looking statements that are
not historical facts within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based
only on our current beliefs, expectations and assumptions regarding
the future of our business, future plans and strategies,
projections, anticipated events and other future conditions. In
some cases you can identify these statements by forward-looking
words such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “could,” “should,” “would,” “project,”
“plan,” “expect,” “goal,” “seek,” “future,” “likely” or the
negative or plural of these words or similar expressions. Examples
of such forward-looking statements include but are not limited to
statements regarding timing and anticipated outcomes of research
and clinical trials for our mitochondria based therapeutic (MBT)
candidates; expectations regarding the growth of MBTs as a
significant future class of drug products; and statements regarding
anticipated therapeutic properties and potential of our
mitochondrial peptide analogs, MBTs and other potential therapies.
You are cautioned that such statements are not guarantees of future
performance and that actual results or developments may differ
materially from those set forth in these forward-looking
statements. Factors that could cause actual results to differ
materially from these forward-looking statements include: our
ability to successfully advance drug discovery and development
programs, including the delay or termination of ongoing clinical
trials and the timing of announcements and updates relating to our
clinical trials and related data; our possible inability to
mitigate the prevalence and/or persistence of the injection site
reactions, receipt of unfavorable feedback from regulators
regarding the safety or tolerability of CB4211 or the possibility
of other developments affecting the viability of CB4211 or CB5138-3
as a clinical candidate or its commercial potential; results that
are different from earlier data results including less favorable
results that may not support further clinical development; our
ability to raise additional capital when necessary to continue our
operations; our ability to recruit and retain key management and
scientific personnel; the risk that our intellectual property may
not be adequately protected; our ability to establish and maintain
partnerships with corporate and industry partners; and risks
related to the impact on our business of the COVID-19 pandemic or
similar public health crises. Additional assumptions, risks and
uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and
Exchange Commission and applicable Canadian securities regulators,
which are available on our website, and at www.sec.gov or
www.sedar.com. You are cautioned that such statements are not
guarantees of future performance and that our actual results may
differ materially from those set forth in the forward-looking
statements. The forward-looking statements and other information
contained in this news release are made as of the date hereof and
CohBar does not undertake any obligation to update publicly or
revise any forward-looking statements or information, whether as a
result of new information, future events or otherwise, unless so
required by applicable securities laws. Nothing herein shall
constitute an offer to sell or the solicitation of an offer to buy
any securities.
Contacts: Jordyn TaraziDirector of Investor
RelationsCohBar, Inc.(650) 445-4441Jordyn.tarazi@cohbar.com
Media:Nancy ThompsonVorticom,
Inc.(212)532-2208Nancyt@vorticom.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024